Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01471704 · ClinicalTrials.gov registry record · Phase 1
Study Investigating the Pharmacokinetic Interaction Between INX-08189 and Verapamil HCL ER in Healthy Volunteers
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT01471704 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 24 participants.
The verdict
NCT01471704, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the potential for a pharmacokinetic (PK) drug-drug interaction between INX-08189 and extended release verapamil hydrochloride (verapamil HCL ER).
Interventions
- DRUG INX-08189 50 mg
- DRUG 240 mg verapamil HCL ER
- DRUG 50 mg dose of INX-08189 and 240 mg verapamil HCL ER
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2011-10 |
| Est. Completion | 2011-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01471704
The ClinicalTrials.gov registry entry for NCT01471704 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which INX-08189 50 mg is the first listed.
NCT01471704 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01471704 about?
NCT01471704 is a clinical study titled "Study Investigating the Pharmacokinetic Interaction Between INX-08189 and Verapamil HCL ER in Healthy Volunteers". The purpose of this study is to evaluate the potential for a pharmacokinetic (PK) drug-drug interaction between INX-08189 and extended release verapamil hydrochloride (verapamil HCL ER).
What is the current status of trial NCT01471704?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2011-10. Estimated completion is 2011-11.
What interventions are being tested in trial NCT01471704?
The interventions under investigation include: INX-08189 50 mg (DRUG), 240 mg verapamil HCL ER (DRUG), 50 mg dose of INX-08189 and 240 mg verapamil HCL ER (DRUG).
Who is sponsoring clinical trial NCT01471704?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.